Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of SPR720 in Healthy Volunteers
NCT03796910Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Dec 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fobrepodacin in nontuberculous mycobacterial pulmonary disease (NTM-PD) (4 arms), sponsored by Spero Therapeutics. Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2018; status: completed.
02
Drugs
fobrepodacin
03
Conditions
nontuberculous mycobacterial pulmonary disease (NTM-PD)
Beyond the preview
Go deeper on NCT03796910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796910.